medigraphic.com
ISSN 0188-9796 (Print)

2000, Number 2

<< Back

Rev Endocrinol Nutr 2000; 8 (2)

Physiophatology of postmenopausal osteoporosis

Arzac PJP

Language: Spanish
References: 17
Page: 73-76
PDF size: 129.65 Kb.


ABSTRACT

Posmenopausal osteoporosis physiopathology is a complex problem which poses an enormous challenge to modern medicine, like other multifactorial pathologies because a wide variety of substances are involved, much of them are intensively investigated in different parts of the world today and are well known, others are still ignored and await to be discover in the future. Research is involved today in genetic factors, calcium, estrogens, prostaglandins, cytokines, insulin-like growth factors, nitric oxide and others.


REFERENCES

  1. Tobias JH, Cook DG, Chambers TJ, Dalzell N. A comparison of bone mineral density between Caucasian, Asian and Afro-Caribbean women. Clinical Science 1994; 87:587-591.

  2. Barthe N, Basse-Cathalinat B, Meunier PJ, Ribot C et al. Measurement of bone mineral density in Mother-Daughter pairs for evaluating the family influence on bone mass acquisition: A GRIO Survey. Osteoporos Int 1998; 8: 379-384.

  3. Deng HW, Chen WM, Recker S et al. Direct evidence of genetic determination of osteoporotic fractures. J Bone Miner Res 1999; Suppl 1: 1171.

  4. Seeman E, Hooper JL, Young NR et al. Do genetic factors contribute to associations between muscle strength, fatfree mass and bone density? A twin study. Am J Physiol 1996; 270: E320-7.

  5. Nordin BEC. Osteomalacia, osteoporosis, and calcium deficiency. Clin Orthop 1960; 17: 235-58.

  6. Morris HA, Need AG, Horowitz M et al. Calcium absorption in normal and osteoporotic postmenopausal women. Calcif Tissue Int 1991; 49: 240-3.

  7. Morris HA, Need AG, Horowitz M et al. Calcium absorption in normal and osteoporotic postmenopausal bone. Calcif Tissue Int 1991; 49: 240-3.

  8. Allbright F, Reifestein S Jr. Posmenopausal osteoporosis. JAMA 1941; 116: 2465-2468.

  9. Suda T, Miyaura C. Patogenesis of bone loss due to estrogen deficiency. Osteoporos Int 1997; (Suppl. 3): S43-S46.

  10. Pacifici R. Review. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 1996; 11: 1043-51.

  11. Takahashi N, Udagawa N, Akatsu T et al. Role of colony stimulating factors in osteoclast development. J Bone Miner Res 1991; 6: 977-85.

  12. Chenu C, Pfeilschifter J, Mundy GR, Roodman GD. Transforming growth factor B inhibits formation of osteoclast-like cells in long term human bone marrow cultures. Proc Natl Acad Sci USA 1988; 85: 5683-7.

  13. Teitelbaum SL, Tanaka H, Mimura M et al. Integrins and osteoclast polarization. Osteoporos Int 1997; (Suppl. 3): S54-S56.

  14. Sunil JW. Effects of nitric oxide donor, nitroglicerin, on prevention of osteoporosis in humans. A clinical study. J Bone Miner Res 1999; Suppl 1: SA389.

  15. Rosen CJ, Donahue LR. Insuline growth factors: Potential therapeutic options for osteoporosis. Trends Endocrin Metab 1995; 6: 235-240.

  16. Schussheim DH, Kulak CAM, Kurland E et al. Decreased serum insulin-like growth factor-1 levels are associated with low bone mass in young women. J Bone Miner Res 1999; Suppl 1, SA328.

  17. Garnero P, Sornay-Rendu E, Delmas PD. Low serum IGF-1, but not IGF BP3, is a strong predictor of osteoporotic fractures. J Bone Miner Res 1999; Suppl: T267.




2020     |     www.medigraphic.com